249 related articles for article (PubMed ID: 30355687)
1. Murine Leukemia Virus Glycosylated Gag Reduces Murine SERINC5 Protein Expression at Steady-State Levels via the Endosome/Lysosome Pathway to Counteract SERINC5 Antiretroviral Activity.
Li S; Ahmad I; Shi J; Wang B; Yu C; Zhang L; Zheng YH
J Virol; 2019 Jan; 93(2):. PubMed ID: 30355687
[TBL] [Abstract][Full Text] [Related]
2. HIV-1 Nef Antagonizes SERINC5 Restriction by Downregulation of SERINC5 via the Endosome/Lysosome System.
Shi J; Xiong R; Zhou T; Su P; Zhang X; Qiu X; Li H; Li S; Yu C; Wang B; Ding C; Smithgall TE; Zheng YH
J Virol; 2018 Jun; 92(11):. PubMed ID: 29514909
[TBL] [Abstract][Full Text] [Related]
3. The Nef-like effect of murine leukemia virus glycosylated gag on HIV-1 infectivity is mediated by its cytoplasmic domain and depends on the AP-2 adaptor complex.
Usami Y; Popov S; Göttlinger HG
J Virol; 2014 Mar; 88(6):3443-54. PubMed ID: 24403584
[TBL] [Abstract][Full Text] [Related]
4. The retroviral accessory proteins S2, Nef, and glycoMA use similar mechanisms for antagonizing the host restriction factor SERINC5.
Ahmad I; Li S; Li R; Chai Q; Zhang L; Wang B; Yu C; Zheng YH
J Biol Chem; 2019 Apr; 294(17):7013-7024. PubMed ID: 30862674
[TBL] [Abstract][Full Text] [Related]
5. Potent Enhancement of HIV-1 Replication by Nef in the Absence of SERINC3 and SERINC5.
Wu Y; Olety B; Weiss ER; Popova E; Yamanaka H; Göttlinger H
mBio; 2019 Jun; 10(3):. PubMed ID: 31186327
[TBL] [Abstract][Full Text] [Related]
6. Functional Interplay Between Murine Leukemia Virus Glycogag, Serinc5, and Surface Glycoprotein Governs Virus Entry, with Opposite Effects on Gammaretroviral and Ebolavirus Glycoproteins.
Ahi YS; Zhang S; Thappeta Y; Denman A; Feizpour A; Gummuluru S; Reinhard B; Muriaux D; Fivash MJ; Rein A
mBio; 2016 Nov; 7(6):. PubMed ID: 27879338
[TBL] [Abstract][Full Text] [Related]
7. Feline Leukemia Virus-B Envelope Together With its GlycoGag and Human Immunodeficiency Virus-1 Nef Mediate Resistance to Feline SERINC5.
Cano-Ortiz L; Gu Q; de Sousa-Pereira P; Zhang Z; Chiapella C; Twizerimana AP; Lin C; Franco AC; VandeWoude S; Luedde T; Baldauf HM; Münk C
J Mol Biol; 2022 Mar; 434(6):167421. PubMed ID: 34954236
[TBL] [Abstract][Full Text] [Related]
8. A Conserved Acidic-Cluster Motif in SERINC5 Confers Partial Resistance to Antagonism by HIV-1 Nef.
Stoneham CA; Ramirez PW; Singh R; Suarez M; Debray A; Lim C; Jia X; Xiong Y; Guatelli J
J Virol; 2020 Mar; 94(7):. PubMed ID: 31941773
[TBL] [Abstract][Full Text] [Related]
9. SERINC5 Potently Restricts Retrovirus Infection
Timilsina U; Umthong S; Lynch B; Stablewski A; Stavrou S
mBio; 2020 Jul; 11(4):. PubMed ID: 32665269
[TBL] [Abstract][Full Text] [Related]
10. SERINC3 and SERINC5 restrict HIV-1 infectivity and are counteracted by Nef.
Usami Y; Wu Y; Göttlinger HG
Nature; 2015 Oct; 526(7572):218-23. PubMed ID: 26416733
[TBL] [Abstract][Full Text] [Related]
11. Identification of SERINC5-001 as the Predominant Spliced Isoform for HIV-1 Restriction.
Zhang X; Zhou T; Yang J; Lin Y; Shi J; Zhang X; Frabutt DA; Zeng X; Li S; Venta PJ; Zheng YH
J Virol; 2017 May; 91(10):. PubMed ID: 28275190
[TBL] [Abstract][Full Text] [Related]
12. MLV glycosylated-Gag is an infectivity factor that rescues Nef-deficient HIV-1.
Pizzato M
Proc Natl Acad Sci U S A; 2010 May; 107(20):9364-9. PubMed ID: 20439730
[TBL] [Abstract][Full Text] [Related]
13. Restriction of Influenza A Virus by SERINC5.
Lai KK; Munro JB; Shi G; Majdoul S; Compton AA; Rein A
mBio; 2022 Dec; 13(6):e0292322. PubMed ID: 36409124
[TBL] [Abstract][Full Text] [Related]
14. TIM-mediated inhibition of HIV-1 release is antagonized by Nef but potentiated by SERINC proteins.
Li M; Waheed AA; Yu J; Zeng C; Chen HY; Zheng YM; Feizpour A; Reinhard BM; Gummuluru S; Lin S; Freed EO; Liu SL
Proc Natl Acad Sci U S A; 2019 Mar; 116(12):5705-5714. PubMed ID: 30842281
[TBL] [Abstract][Full Text] [Related]
15. SERINC as a Restriction Factor to Inhibit Viral Infectivity and the Interaction with HIV.
Gonzalez-Enriquez GV; Escoto-Delgadillo M; Vazquez-Valls E; Torres-Mendoza BM
J Immunol Res; 2017; 2017():1548905. PubMed ID: 29359168
[TBL] [Abstract][Full Text] [Related]
16. An N-Glycosylated Form of SERINC5 Is Specifically Incorporated into HIV-1 Virions.
Sharma S; Lewinski MK; Guatelli J
J Virol; 2018 Nov; 92(22):. PubMed ID: 30158294
[TBL] [Abstract][Full Text] [Related]
17. Nef homodimers down-regulate SERINC5 by AP-2-mediated endocytosis to promote HIV-1 infectivity.
Staudt RP; Smithgall TE
J Biol Chem; 2020 Nov; 295(46):15540-15552. PubMed ID: 32873704
[TBL] [Abstract][Full Text] [Related]
18. IFITM3 Reduces Retroviral Envelope Abundance and Function and Is Counteracted by glycoGag.
Ahi YS; Yimer D; Shi G; Majdoul S; Rahman K; Rein A; Compton AA
mBio; 2020 Jan; 11(1):. PubMed ID: 31964738
[TBL] [Abstract][Full Text] [Related]
19. S2 from equine infectious anemia virus is an infectivity factor which counteracts the retroviral inhibitors SERINC5 and SERINC3.
Chande A; Cuccurullo EC; Rosa A; Ziglio S; Carpenter S; Pizzato M
Proc Natl Acad Sci U S A; 2016 Nov; 113(46):13197-13202. PubMed ID: 27803322
[TBL] [Abstract][Full Text] [Related]
20. HIV-1 Nef promotes infection by excluding SERINC5 from virion incorporation.
Rosa A; Chande A; Ziglio S; De Sanctis V; Bertorelli R; Goh SL; McCauley SM; Nowosielska A; Antonarakis SE; Luban J; Santoni FA; Pizzato M
Nature; 2015 Oct; 526(7572):212-7. PubMed ID: 26416734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
